Home > Boards > US Listed > Biotechs > Biohaven Pharmceuticals (BHVN)

From Dew Diligence, 9/28/2021:

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
north40000 Member Profile
Member Level 
Followed By 216
Posts 17,261
Boards Moderated 0
Alias Born 01/19/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:34:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:29:18 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:27:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 4:27:00 PM
Biohaven, Artizan to work on Parkinson's drug discovery program Seeking Alpha - 11/18/2021 8:23:52 AM
Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic Development Program in Parkinson’s Disease GlobeNewswire Inc. - 11/18/2021 7:30:00 AM
Biohaven's migraine med Nurtec approved in Kuwait Seeking Alpha - 11/17/2021 7:10:54 AM
NURTEC® ODT Approved In Kuwait For Acute Treatment Of Migraine PR Newswire (US) - 11/17/2021 6:57:00 AM
Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital PR Newswire (US) - 11/15/2021 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/10/2021 6:19:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/9/2021 4:29:29 PM
Biohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout Seeking Alpha - 11/9/2021 9:06:59 AM
Biohaven, Pfizer in Collaboration to Commercialize Rimegepant Dow Jones News - 11/9/2021 8:47:00 AM
Biohaven Pharmaceuticals EPS beats by $0.11, beats on revenue Seeking Alpha - 11/9/2021 8:33:16 AM
Pfizer to gains ex-U.S. rights to Biohaven migraine med Nurtec in up to $1.24B deal Seeking Alpha - 11/9/2021 8:13:16 AM
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States PR Newswire (US) - 11/9/2021 7:46:00 AM
Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments PR Newswire (US) - 11/9/2021 7:45:00 AM
Biohaven Pharmaceuticals Q3 2021 Earnings Preview Seeking Alpha - 11/8/2021 11:47:53 AM
Biohaven To Report Third Quarter 2021 Financial Results And Recent Business Developments On November 9, 2021 PR Newswire (US) - 11/4/2021 7:30:00 AM
Nine Line Apparel and Biohaven's Nurtec ODT Set to Honor World War II Veterans Ahead of 80th Anniversary at Phoenix Raceway PR Newswire (US) - 11/2/2021 7:30:00 AM
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma PR Newswire (US) - 10/27/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/6/2021 7:01:35 AM
Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The First And Only Migraine Medication For Both Acute And Preventive Treatment PR Newswire (US) - 10/5/2021 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/1/2021 5:11:13 PM
Biohaven Pharmaceutical, ASLAN Pharmaceuticals among major healthcare premarket losers' pack Seeking Alpha - 9/27/2021 8:15:35 AM
north40000 Member Level  Wednesday, 09/29/21 04:50:21 PM
Re: None
Post # of 21 
From Dew Diligence, 9/28/2021:

FDA approves ABBV’s Qulipta—(atogepant)—for migraine prevention:

https://finance.yahoo.com/news/fda-approves-qulipta-atogepant-first-224200797.html

Qulipta will compete with BHVN’s Nurtec ODT, which is approved for both prevention and acute treatment (#msg-164076435, #msg-154072129).

ABBV now has three approved agents in its migraine portfolio: Qulipta; Ubrelvy (approved for acute treatment in 2019 [#msg-154072129]); and Botox. All three came to ABBV by way of Allergan.


Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences